middle.news
Mesoblast Launches Ryoncil with $48.7M Sales, Cuts Losses, Secures $125M Credit Line
8:54am on Friday 27th of February, 2026 AEDT
•
Healthcare
Read Story
Mesoblast Launches Ryoncil with $48.7M Sales, Cuts Losses, Secures $125M Credit Line
8:54am on Friday 27th of February, 2026 AEDT
Key Points
First commercial sales of Ryoncil generate $48.7 million revenue
Net loss improves 16% to $40.2 million for H1 FY2026
Secures $125 million five-year credit-line facility
Research and development expenses rise with clinical and manufacturing scale-up
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
MESOBLAST (ASX:MSB)
OPEN ARTICLE